Conference
Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248).
Authors
Ringash J; Waldron JN; Siu LL; Martino R; Winquist E; Wright JR; Nabid A; Hay JH; Hammond A; Sultanem K
Volume
33
Pagination
pp. 6053-6053
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2015
DOI
10.1200/jco.2015.33.15_suppl.6053
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X